Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model.
Saved in:
| Title: | Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model. |
|---|---|
| Authors: | Varghese B; Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA.; Sana Biotechnology Inc., Boston, MA, USA., Lynch L; Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA.; Brigham and Women's Hospital, 75 Francis St., NRB 6, Boston, MA, 02115, USA., Vriend LE; Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA., Draganov D; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Sanofi Inc., San Diego, CA, USA., Clark JM; Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA., Kissick HT; Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA.; Emory University, Atlanta, GA, USA., Varghese S; Medical Center School of Medicine and Dentistry, University of Rochester, Rochester, NY, 14642, USA., Sanda MG; Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA.; Emory University, Atlanta, GA, USA., Dranoff G; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Novartis Biomedical Institutes of Research, Cambridge, MA, USA., Arredouani MS; Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA.; Intellia Inc., Cambridge, MA, USA., Balk SP; Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA. sbalk@bidmc.harvard.edu., Exley MA; Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA. mexley@partners.org.; Brigham and Women's Hospital, 75 Francis St., NRB 6, Boston, MA, 02115, USA. mexley@partners.org.; Imvax Inc., Philadelphia, PA, USA. mexley@partners.org.; University of Manchester, Manchester, UK. mexley@partners.org.; MiNK Therapeutics Inc., New York, NY, USA. mexley@partners.org. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2022 Dec; Vol. 71 (12), pp. 2943-2955. Date of Electronic Publication: 2022 May 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-022-03210-8 |
